These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3994898)

  • 41. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407.
    Lee YS; Yoon JN; Yoon IS; Lee MG; Kang HE
    Xenobiotica; 2012 Aug; 42(8):766-74. PubMed ID: 22300394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
    Moreland TA; McMurdo ME; McEwen J
    Biopharm Drug Dispos; 1989; 10(3):311-9. PubMed ID: 2720134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.
    Somogyi A; Albrecht M; Kliems G; Schäfer K; Eichelbaum M
    Br J Clin Pharmacol; 1981 Jul; 12(1):51-60. PubMed ID: 7248141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.
    Eichelbaum M; Somogyi A
    Eur J Clin Pharmacol; 1984; 26(1):47-53. PubMed ID: 6714292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pharmacokinetics of racemic verapamil in patients with impaired renal function.
    Zachariah PK; Moyer TP; Theobald HM; Frantz RP; Kurtz SB; McCarthy JT; Smith RL
    J Clin Pharmacol; 1991 Jan; 31(1):45-53. PubMed ID: 2045528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical pharmacokinetics of verapamil.
    Hamann SR; Blouin RA; McAllister RG
    Clin Pharmacokinet; 1984; 9(1):26-41. PubMed ID: 6362951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia.
    Narang PK; Blumhardt CL; Doran AR; Pickar D
    Clin Pharmacol Ther; 1988 Nov; 44(5):550-7. PubMed ID: 3180637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic availability of oral verapamil and effect on PR interval in man.
    Johnston A; Burgess CD; Hamer J
    Br J Clin Pharmacol; 1981 Sep; 12(3):397-400. PubMed ID: 7295469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Verapamil pharmacokinetics and apparent hepatic and renal blood flow.
    Meredith PA; Elliott HL; Pasanisi F; Kelman AW; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1985 Aug; 20(2):101-6. PubMed ID: 4041329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.
    Padrini R; Barbieri E; Piovan D; Toffoli M; Motta A; Trevi GP; Ferrari M
    Eur J Clin Pharmacol; 1985; 28(6):653-7. PubMed ID: 4065190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determination of verapamil and norverapamil in human biological material. Investigation of plasma concentrations after oral administration of two different verapamil formulations.
    Horne C; Spahn H; Mutschler E; Knauf H
    Arzneimittelforschung; 1987 Aug; 37(8):956-9. PubMed ID: 3675692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regiochemistry and enantioselectivity in the oxidative N-dealkylation of verapamil.
    Nelson WL; Olsen LD
    Drug Metab Dispos; 1988; 16(6):834-41. PubMed ID: 2907462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
    Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
    Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of cimetidine on verapamil disposition.
    Loi CM; Rollins DE; Dukes GE; Peat MA
    Clin Pharmacol Ther; 1985 Jun; 37(6):654-7. PubMed ID: 4006365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
    Wang YH; Jones DR; Hall SD
    Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
    Piao YJ; Choi JS
    Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose proportionality of pharmacokinetics with a cr-verapamil formulation.
    Mulligan S; Devane J; Martin M
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():304-11. PubMed ID: 1820898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats.
    Xie SS; Hu N; Jing XY; Liu XD; Xie L; Wang GJ; Liu CH
    J Pharm Pharmacol; 2010 Apr; 62(4):440-7. PubMed ID: 20604832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
    Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
    J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.